Opening book details…
Can I read News at XI: moving beyond factor Xa inhibitors on EtoBox?
News at XI: moving beyond factor Xa inhibitors by James C. Fredenburgh; Jeffrey I. Weitz is a Medicine article available to read on EtoBox.
What is News at XI: moving beyond factor Xa inhibitors about?
Oral anticoagulants are a mainstay for the prevention and treatment of arterial and venous thrombosis. Direct oral anticoagulants (DOACs) have replaced vitamin K antagonists (VKAs) for many indications. Currently available DOACs include dabigatran, which inhibits thrombin, and apixaban, edoxaban, and rivaroxaban, which inhibit factor (F) Xa. A new class of DOACs is under development. These new DOACs, which include asundexian and milvexian, inhibit FXIa, which is positioned in the intrinsic pathway of coagulation. Anticoagulants that target FXIa have the potential to be safer than the current DOACs because there is emerging evidence that FXI is essential for thrombosis but mostly dispensable for hemostasis. In addition to the oral inhibitors of FXIa, parenteral inhibitors also are under development. These include fesomersen, an antisense oligonucleotide that reduces the hepatic synthesis of FXI, abelacimab, an antibody that binds FXI and blocks its activation, and osocimab, an FXIa inhibitory antibody. Focusing on these new agents, this paper (a) describes the unmet needs in oral anticoagulation therapy, (b) explains why FXI is a promising target for new oral anticoagulants, (c) rev
Who reads News at XI: moving beyond factor Xa inhibitors?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- James C. Fredenburgh; Jeffrey I. Weitz
- Publisher
- Elsevier BV
- Published
- 2023
- Language
- EN
- Field
- Medicine (Health Sciences)